Literature DB >> 10935849

The economic cost of epilepsy: a review.

M Brunetti1, E Pagano, L Garattini.   

Abstract

Epilepsy is the most prevalent chronic neurologic condition. In developed countries, its incidence is 30-50 per 100,000 population per year and the prevalence is approximately 5-8 cases per 1,000 population. The rapid growth of health care expenditures has led to increased interest in economic evaluation of health care programs. We reviewed studies on the costs of epilepsy to assess the significance of their quantitative results, through a specific scheme of analysis. The main findings of our study are that a general consensus on cost of illness evaluation is still remote and many studies lack technical details, making difficult any useful comparison of results. New efforts should be realized to achieve a major degree of standardization in methodological processes.

Entities:  

Mesh:

Year:  1998        PMID: 10935849     DOI: 10.1007/bf02427569

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  13 in total

1.  A practical guide for calculating indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

2.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

3.  Cost-of-illness studies: a major headache?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

4.  The cost of migraine: more than just a headache?

Authors:  P J Davey; S R Leeder
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

5.  Economic evaluation in healthcare. A brief history and future directions.

Authors:  K Blumenschein; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

6.  The concept of cost in the economic evaluation of health care. A theoretical inquiry.

Authors:  M Johannesson
Journal:  Int J Technol Assess Health Care       Date:  1994       Impact factor: 2.188

7.  Cost-of-illness studies: fact or fiction?

Authors:  D P Rice
Journal:  Lancet       Date:  1994-12-03       Impact factor: 79.321

8.  The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies.

Authors:  O C Cockerell; Y M Hart; J W Sander; S D Shorvon
Journal:  Epilepsy Res       Date:  1994-07       Impact factor: 3.045

Review 9.  The epidemiology and treatment of chronic and refractory epilepsy.

Authors:  S D Shorvon
Journal:  Epilepsia       Date:  1996       Impact factor: 5.864

10.  Cost of epilepsy in the United States: a model based on incidence and prognosis.

Authors:  C E Begley; J F Annegers; D R Lairson; T F Reynolds; W A Hauser
Journal:  Epilepsia       Date:  1994 Nov-Dec       Impact factor: 5.864

View more
  2 in total

Review 1.  Cost of epilepsy: a systematic review.

Authors:  Adam Strzelczyk; Jens Peter Reese; Richard Dodel; Hajo M Hamer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 2.  The economic impact of epilepsy: a systematic review.

Authors:  Katharina Allers; Beverley M Essue; Maree L Hackett; Janani Muhunthan; Craig S Anderson; Kristen Pickles; Franziska Scheibe; Stephen Jan
Journal:  BMC Neurol       Date:  2015-11-25       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.